Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation

Documenti analoghi

• Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
  di: Okabe, Seiichi, et al.
  Pubblicazione: (2016)
• Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
  di: Okabe, Seiichi, et al.
  Pubblicazione: (2014)
• Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
  di: Okabe, Seiichi, et al.
  Pubblicazione: (2013)
• Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells
  di: Okabe, Seiichi, et al.
  Pubblicazione: (2015)
• Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
  di: Okabe, Seiichi, et al.
  Pubblicazione: (2018)